Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer. - Walter, Adam; Rocconi, Rodney P.; Monk, Bradley J.; Herzog, Thomas J.; Manning, Luisa; Bognar, Ernest; Wallraven, Gladice; Aaron, Phylicia; Horvath, Staci; Tang, Min; Stanbery, Laura; Coleman, Robert L.; et al. (Gynecologic Oncology, 2021)